What one share of ADC Therapeutics SA holds
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC.
ADC Therapeutics SA’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.53 |
|---|---|
| Profit | −$0.65 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.69 |
| Cash and investments | $1.72 |
| Book value | −$1.79 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $0.02 | −$2.64 | $0.02 | −$2.62 | — | $2.64 |
| 2019 | $0.05 | −$2.36 | $0.01 | −$2.47 | — | $2.13 |
| 2020 | $0.00 | −$3.77 | $0.01 | −$2.59 | — | $4.37 |
| 2021 | $0.44 | −$3.00 | $0.04 | −$3.09 | — | $2.01 |
| 2022 | $2.69 | −$2.01 | — | — | — | $0.99 |
| 2023 | $0.85 | −$2.94 | $0.04 | −$1.49 | — | −$1.80 |
| 2024 | $0.73 | −$1.62 | $0.01 | −$1.28 | — | −$2.05 |
| 2025 | $0.64 | −$1.12 | $0.00 | −$1.11 | — | −$1.48 |
Common questions about ADC Therapeutics SA
How much does one share of ADC Therapeutics SA earn?
Over the last 12 months, ADC Therapeutics SA lost $0.65 for each share on $0.53 of sales.
Does ADC Therapeutics SA pay a dividend?
ADC Therapeutics SA didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is ADC Therapeutics SA’s book value per share?
ADC Therapeutics SA’s book value is negative (−$1.79 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of ADC Therapeutics SA have?
Each share of ADC Therapeutics SA has $1.72 of cash and investments, as of June 30, 2026.
What is ADC Therapeutics SA’s free cash flow per share?
−$0.69 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has ADC Therapeutics SA bought back shares?
ADC Therapeutics SA’s share count rose about 173% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.